Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 combinations as first-line therapy for unresectable hepatocellular carcinoma
CTR20182026Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Nov 2018; status: completed.
02
Drugs
penpulimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20182026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182026.